Study evaluates 18F-DCFPyL in BCR prostate cancer


The PSMA-targeting PET agent 18F-DCFPyL may effectively find recurrent lesions in patients with prostate cancer who had biochemical recurrence, researchers reported at the 2021 American Urological Association virtual annual meeting. "18F-DCFPyL PET/CT holds great potential to be a 'one-stop shop' diagnostic tool in the work-up of BCR prostate cancer to identify possible extra-pelvic oligometastases for locally targeted therapy," according to researchers.

Full story:

SNMMI SmartBrief

Nuclear medicine, molecular imaging and therapy

Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession.